Immuron delivers improved revenue and sharply improved cash position in FY26 preliminary results
In its FY26 preliminary results presentation, Immuron Limited (NASDAQ: IMRN, ASX: IMC) outlined a full-year performance update from CEO Steven Lydeamore covering the period ended 30 June 2026, headlined by global sales revenue of $7.7m (up 6%) and a cash balance of $9.0m, a $6.2m improvement year-on-year.
The presentation also detailed a net loss of $(3.8)m, representing a $1.4m improvement on the prior year, signalling narrowing losses rather than a return to profitability. Management noted that FY26 results are preliminary and subject to audit review.
The strengthened balance sheet, combined with revenue growth across all geographies, was framed as underpinning the company’s strategic reset toward profitability and reduced cash burn.
When big ASX news breaks, our subscribers know first
FY26 financial results at a glance
The presentation set out a full-year financial scorecard showing revenue gains across every reporting region alongside a materially stronger cash position. Management flagged that $3.0m was held in term deposits at 30 June 2025, with nil held at 30 June 2026, providing context for the reported cash improvement.
| Metric | FY26 Result | Movement |
|---|---|---|
| Global Sales Revenue | $7.7m | Up 6% |
| Australian Sales Revenue | $5.8m | Up 10% |
| US Sales Revenue | $1.8m | Up 7% (up 13% in USD) |
| Gross Profit Margin | 64.5% | Down 0.9% |
| Net Profit/(Loss) | $(3.8)m | $1.4m improvement |
| Cash | $9.0m | $6.2m improvement |
The 0.9% dip in gross profit margin was minor, with margins remaining strong at 64.5%. US revenue growth was particularly notable, up 7% in reported terms and 13% measured in USD.
The full-year result was built on four consecutive quarters of growth, with Canada delivering Q4 FY26 sales up 427% on the prior comparable period as genuine consumer demand built through the retail channel following the earlier pipeline fill into 1,000+ doors.
Clinical progress and operational milestones
The presentation detailed several clinical and operational highlights achieved during FY26, spanning both the regulated pipeline and the commercial product portfolio.
Key items outlined by management include:
-
FDA approval of the IMM-529 IND
-
Travelan® n=851 trial completed
-
New U.S. Department of Defense subaward
-
New product launched in Australia: PROIBS
-
Strategic reset aimed at profitability and reduced cash burn
-
Engagement of Pullan Consulting to support partnering IMM-529
The FDA IND approval and the completed Travelan® trial were achieved during the year. The engagement of Pullan Consulting was positioned as supporting efforts to partner IMM-529, though no partnering deal was disclosed.
Management commentary
The FY26 presentation emphasised a strategic reset prioritising profitability and reduced cash burn, with management framing revenue growth and the strengthened cash position as the foundation for that transition.
What Travelan and IMM-529 mean for Immuron
Immuron is a commercial-stage biopharmaceutical company that combines a marketed gut-health and immunology product, Travelan®, generating real sales revenue, with a clinical pipeline that includes IMM-529.
The IMM-529 IND was approved by the FDA during FY26.
The IMM-529 partnering strategy involves Pullan Consulting, a specialist firm with a 20-year track record of executing partnering transactions, working to secure a licensee for the asset against a projected base-case revenue opportunity of US$400 million annually.
The Travelan® trial with a sample size of 851 participants was completed during the year.
FY27 outlook and funding position
Management outlined its stated priorities for FY27, focused on building on the FY26 revenue momentum while continuing to improve financial performance.
The presentation set out the following FY27 priorities:
-
Continued Travelan® sales growth
-
Portfolio expansion
-
Geographic sales expansion
-
Continued improvement in profitability and reduced cash burn
On funding, management stated that the current cash position is sufficient to fund operations through FY27–FY28.
The FY26 presentation set out an investment case built on a growing revenue base, a strengthened cash position, and narrowing losses. Clinical catalysts, including efforts to partner IMM-529 and the completed Travelan® dataset, add pipeline optionality on top of the commercial engine driving the strategic reset.
Ready to Explore the Investment Case Behind Immuron’s FY26 Reset?
Immuron has delivered six consecutive quarters of revenue growth, a $6.2m improvement in cash position, and FDA IND approval for IMM-529 — all while narrowing its net loss to $(3.8)m in FY26. With a commercial product generating $7.7m in global sales and a partnering strategy targeting a US$400m annual revenue opportunity, the strategic reset toward profitability is underway.
For a deeper look at the company’s financial results, pipeline progress, and FY27 priorities, visit the Immuron investor centre to access the full suite of investor materials and announcements.